Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023

Eckert & Ziegler SE, a prominent player in the field of radiopharmaceuticals and isotope-related components, has reported significant growth in its annual financial results for 2023. The company achieved sales of €246.1 million, marking an 11% increase or €23.8 million compared to the previous year. Furthermore, the earnings before interest and taxes (EBIT) from continuing operations before special items reached €46.9 million, with a net profit of €26.3 million, translating to earnings per share of €1.26.

Notably, the Medical segment witnessed a substantial increase, with sales rising by 27% to €115.2 million, driven by strong demand for radiopharmaceuticals. Meanwhile, the Isotope Products segment maintained its performance with sales of €130.9 million. Looking ahead to the 2024 financial year, Eckert & Ziegler's Executive Board anticipates sales to approach €265 million and EBIT from continuing operations to be around €50 million before special items.